关键词: font-size:medium, ">原发性骨质疏松；地舒单抗；阿仑膦酸钠；骨密度

Abstract: Objective： To explore the effects of desumab combined with alendronate sodium on bone mineral density and bone metabolism indicators in patients with primary osteoporosis. Methods： A retrospective analysis was conducted on 113 patients with primary osteoporosis in our hospital (from January 2023 to August 2024)， and they were divided into the control group (57 cases) and the observation group (56 cases) according to the treatment plan. The control group was treated with alendronate sodium， while the observation group was treated with desumab on the above basis. The clinical efficacy， bone mineral density， bone metabolism indicators [serum osteocalcin (BGP)， bone alkaline phosphatase (BAP)， type I collagen cross-linked C-terminal peptide (CTX)]， inflammatory factors [interleukin-1 (IL-1)， interleukin-6 (IL-6)， tumor necrosis factor (TNF-α)]， and the incidence of adverse reactions were compared between the two groups. Results： After the treatment， the clinical efficacy of the observation group was higher than that of the control group (P<0.05)； After the treatment， the bone mineral density of normal L2-L4 in the hip， femoral neck and lumbar vertebrae in the observation group was higher than that in the control group (P<0.05)； After the treatment， BGP， BAP， CTX， IL-1， IL-6 and TNF-α in the observation group were lower than those in the control group (P<0.05)； There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period (P>0.05). Conclusion： The application of desumab combined with alendronate sodium in patients with primary osteoporosis can improve the clinical efficacy， increase bone density， improve bone metabolism， reduce inflammatory responses， and is safe.

Key words: font-size:medium, ">Primary osteoporosis； Desumab； Sodium alendronate； Bone mineral density